>GILEAD Aktienkurs 
58.40 EUR    -0.7%    (Tradegate)
Ask: 58.44 EUR / 171 Stück
Bid: 58.30 EUR / 171 Stück
Tagesumsatz: 22793 Stück
Realtime Kurs von 8 bis 22 Uhr!
>GILEAD Performance
1 Woche: -4,1%
1 Monat: -13,4%
3 Monate: -18,3%
6 Monate: -7,7%
1 Jahr: -0,2%
laufendes Jahr: -0,8%
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US3755581036 / 885823
Symbol/ Ticker:  GIS (Frankfurt) / GILD (NASDAQ)
Index:  S&P500, Nasdaq100
Marktkapitalisierung:  72700 Mio. EUR
Umsatz:  18807.74 Mio. EUR
EBITDA:  4716.78 Mio. EUR
Gewinn je Aktie:  -0.17 EUR
Schulden:  20445.04 Mio. EUR
Liquide Mittel:  16423.9 Mio. EUR
Umsatz-/ Gewinnwachstum:  -9.50% / -
KGV/ KGV lG:  18.45 / 10.2
KUV/ KBV/ PEG:  3.92 / 4.75 / 0.47
Gewinnm./ Eigenkapitalr.:  -1.16% / -1.40%
Dividende je Aktie:  1.17 EUR
Dividendenrendite/ -schätzung:  2% / 3.95%
Div. Historie:  12.03.20 - 0.599€
12.09.19 - 0.571€
13.06.19 - 0.557€
13.09.18 - 0.492€
Letzte Datenerhebung:  09.08.20
>GILEAD Eigentümer
Aktien: 1250 Mio. St.
f.h. Aktien: 1250 Mio. St.
Insider Eigner: 0.41%
Instit. Eigner: 80.77%
Leerverk. Aktien: 1.76%
 >GILEAD Anleihen 
Es sind 4 Anleihen zur GILEAD Aktie bekannt.
>GILEAD Peer Group

10.08.20 - 21:19
Gilead Sciences Submits New Drug Application for Remdesivir as a COVID-19 Treatment (Fool)
Right now, the antiviral is being administered to coronavirus patients under an emergency use authorization, which is more limited....
10.08.20 - 18:19
Gilead Sciences files U.S. application for remdesivir for COVID-19 (SeekingAlpha)
Um den gesamten Artikel unter zu lesen, klicken Sie bitte auf die Überschrift...
10.08.20 - 18:01
Gilead Submits New-Drug Application for Remdesivir (The Street)
Um den gesamten Artikel unter zu lesen, klicken Sie bitte auf die Überschrift...
10.08.20 - 15:13
Iran Claims It′s Using a Remdesivir Generic to Fight Covid-19 (Bloomberg)
Iran Claims It's Using a Remdesivir Generic to Fight Covid-19...
10.08.20 - 13:01
Pfizer announces agreement with Gilead to manufacture Remdesivir to treat Covid-19 (PBR)
Under the terms of the agreement, Pfizer will provide contract manufacturing services at Pfizer's McPherson, Kansas facility to manufacture and supply remdesivir for Gilead. In March, Pfizer launched The post Pfizer announces agreement with Gilead ...
09.08.20 - 13:04
A Big Pension Bought GE, Merck and Intel Stock. It Sold This Biotech. (MarketWatch)
The State of Michigan Retirement System bought more General Electric, Merck, and Intel stock in the second quarter, and sold most of its investment in biotech stock Gilead Sciences....
08.08.20 - 04:01
Pfizer to Co-Manufacture Coronavirus Drug Remdesivir (Fool)
The company is pitching in to produce Gilead's antiviral treatment, which received emergency use authorization in May....
07.08.20 - 22:10
Gilead Sciences files for mixed shelf (SeekingAlpha)
Um den gesamten Artikel unter zu lesen, klicken Sie bitte auf die Überschrift...
07.08.20 - 19:55
Gilead Inks Deal to Boost Production of Covid-19 Drug Remdesivir (WSJ EN)
Gilead Sciences Inc. is expanding its manufacturing network to ramp up production of Covid-19 treatment remdesivir, and says it will be able to meet global demand in real time starting in October....
07.08.20 - 18:10
Pfizer to Produce Gilead Virus-Treatment Candidate Remdesivir (The Street)
Um den gesamten Artikel unter zu lesen, klicken Sie bitte auf die Überschrift...
07.08.20 - 17:07
Pfizer Will Help Gilead Make Its Covid-19 Treatment, Remdesivir (MarketWatch)
The drug giant is one of the firms that will manufacture remdesivir, Gilead Sciences’ experimental antiviral that got emergency approval in May as a treatment for Covid-19....
07.08.20 - 16:13
Pfizer, Gilead Strike Multiyear Partnership To Manufacture COVID-19 Drug Remdesivir (Benzinga)
Large-cap biopharma companies Pfizer Inc. (NYSE: PFE) and Gilead Sciences, Inc. read more...
07.08.20 - 16:07
Pharma Giant Pfizer Teams With Gilead To Boost Production Of Covid-19 Drug Remdesivir (Forbes)
The buddy system will help the pharmaceutical companies quickly ramp up production, even as the coronavirus continues to spread....
07.08.20 - 15:31
Pfizer Signs Deal To Boost Supply Of Gilead′s Remdesivir For COVID-19 Patients (RTTNews)
Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients....
07.08.20 - 15:16
NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatment (MarketWatch)
The National Institutes of Health said it will conduct a randomized, controlled clinical trial testing a combination of Gilead Sciences Inc.'s remdesivir with Merck KGaA's interferon beta-1a as a treatment for COVID-19 p......
07.08.20 - 15:13
Pfizer agrees to manufacture Gileads coronavirus drug remdesivir (CNBC)
Um den gesamten Artikel unter zu lesen, klicken Sie bitte auf die Überschrift...
07.08.20 - 14:16
Pfizer to help manufacture Gilead's remdesivir (MarketWatch)
Shares of Pfizer Inc. gained 1.0% in premarket trading on Friday after it announced that it will help manufacture Gilead Sciences Inc.'s COVID-19 treatment remdesivir as part of a multi-year agreement. Gilead's stock was......
07.08.20 - 14:13
Pfizer to manufacture COVID-19 med remdesivir (SeekingAlpha)
Um den gesamten Artikel unter zu lesen, klicken Sie bitte auf die Überschrift...
06.08.20 - 23:49
State Attorneys General Lobby the U.S. to Lower the Cost of Coronavirus Drug Remdesivir (Fool)
The 31 petitioners also want federal agencies to tap third-party manufacturers to help boost the supply....
06.08.20 - 23:13
Gilead says it will be able to make enough remdesivir to meet global coronavirus demand in October (CNBC)
Gilead said it plans to produce more than 2 million treatment courses of the drug by the end of the year and anticipates being able to produce "several million more" in 2021....
>Zitat des Tages: Ich bin kein Schauspieler nicht. Ich geb′ mich immer so, wie ich bin. - Alexander Wurz
Partner:    >Tradegate Börse | >TraderFox Handelssignale | >Heibel-Ticker Börsenbrief | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf Twitter

Copyright @ - Die Märkte im Blick!